BASKING RIDGE, NJ – October 10, 2024 – Reproductive Medicine Associates (RMA), one of the nation’s leading reproductive service providers and a pioneer in IVF research, celebrated its 25th anniversary this month, commemorating a quarter-century of contributing transformative research and evidence-based science to support fertility preservation and infertility treatments with breakthroughs related to single embryo transfer, egg freezing, PGT-A testing, LGBTQ+ care, and more. Since RMA’s founding in 1999, the nationwide fertility network has accomplished life-changing reproductive medicine outcomes, achieved successful pregnancies leading to births of more than 50,000 healthy babies in New Jersey alone and set new standards for the entire industry which have redefined the practice of fertility medicine.
Founded by Drs. Paul Bergh, Richard Scott, and Michael Drews with the opening of the first clinic in Morristown, New Jersey, RMA clinics and IVF laboratories now stretch from coast to coast, with locations in California, Colorado, Florida, New Jersey, Pennsylvania, Texas, and Washington.
“It’s with great pride we announce our 25th anniversary and celebrate RMA’s significant achievements, helping patients realize their family creation dreams and delivering industry-leading patient care driven by evidence-based practices,” said Lynn Mason, CEO of IVI RMA North America. “As we drive the future of fertility medicine, we remain committed to advancing reproductive care to make parenthood possible for more families and continually improving and expanding the RMA network to serve the roughly 1 in 6 Americans who struggle with infertility.”
As it’s grown, RMA has maintained an unwavering commitment to keeping research and scientific excellence at its core. In 2017, RMA merged with Instituto Valenciano de Infertilidad (IVI), forming IVI- RMA Global, the world’s largest assisted reproduction group with over 190 clinical offices and 95 labs in 15 countries, including the U.S., Europe, and Latin America, with a team of over 4500 physicians and over 300 scientists and researchers. In 2023, IVI RMA announced the acquisition of Boston IVF and Toronto-based TRIO, adding 13 labs and 32 offices across the U.S. and Canada to its network, furthering its leadership in North America, and reinforcing the company’s commitment to providing evidence-based fertility solutions.
“The field of reproductive endocrinology is only 50 years old, and for 25 of those years RMA has been a clinical leader, setting a new standard of care for the industry,” added Dr. Thomas Molinaro, Chief Medical Officer of IVI RMA North America.
Throughout every stage of growth, RMA, along with IVI RMA Global, has been relentlessly focused on research, investing tens of millions of dollars into studying and improving the science of IVF and publishing more than 1,000 published research papers to date – including more than a dozen clinical trials—and helping individuals achieve pregnancies on an unparalleled scale, with births of over 300,000 babies worldwide thus far. This unmatched emphasis on research has allowed RMA to make quantum leap advancements in IVF and pioneer single embryo transfers, drastically reducing multiple births and risk for mothers and babies and establishing a new standard of care across the industry.
Added Molinaro, “The next 25 years will surely bring many changes to our space, but what won’t change is our laser focus on putting patients first and using the best science to help them realize their family creation dreams and our position as a force that will continue to shape the future of reproductive care.”
